Proceeding with previously announced plan to enroll 3 to 5 additional patients in Cohort 2 of the ASPIRO Phase 1/2 study and to select the optimal dose of AT132 in the second quarter of 2019
Subsequent to determination of the optimal dose, Audentes plans to provide an updated data package to FDA to facilitate final agreement on the path to BLA submission
PR Newswire
SAN FRANCISCO, Jan. 31, 2019